ArticleBMC ophthalmology2025
Choroidal microvascular dropout and its relationship to progression in primary open-angle and pseudoexfoliation glaucoma.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo compare the longitudinal change of choroidal microvascular dropout (CMvD) and its relationship with glaucoma progression between primary open angle glaucoma (POAG) and pseudoexfoliation glaucoma (PXG).
methodsThe analysis included 114 eyes of 114 patients, with 57 POAG and 57 PXG eyes matched by age and visual field (VF) mean deviation (MD). The angular circumference (AC) of CMvD was measured using the en-face choroidal layer images of optical coherence tomography angiography at baseline and the final follow-up. Progression of CMvD was defined as an increase in AC beyond measurement variability (-3.85° to + 3.28°) or the appearance of new CMvD during follow-up. Glaucoma progression was determined by MD change rate.
resultsThe prevalence of CMvD was significantly higher in POAG than in PXG eyes (68.4% vs. 43.9%, p = 0.008) at baseline. However, by the final visit, the difference in prevalence between the groups was not significant (68.4% vs. 56.1%, p = 0.178). During the study period, seven PXG eyes developed new CMvD. There was no significant difference in MD progression rate between the stable and progressed CMvD subgroups in POAG (-0.7 ± 0.8 dB/year vs. - 0.8 ± 0.5 dB/year, p = 0.715). In contrast, PXG eyes showed a significantly faster MD progression rate in the progressed CMvD subgroup than in those with stable CMvD subgroup (-0.4 ± 0.7 dB/year vs. - 1.2 ± 0.8 dB/year, p = 0.010).
conclusionsThe progression of CMvD was more frequently observed in PXG eyes than POAG eyes and showed association with faster VF progression in PXG eyes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.